Physician profile
Sally Michell Clark
NPI 1295278984
$9,384.89
in general payments reported to CMS, 2019-2025
28 companies · $2,507 in 2025
The $2,507 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $870 · 2022: $1,087 · 2023: $2,070 · 2024: $2,851 · 2025: $2,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,333 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,332.85 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,347.35 | 2021-2025 | Enbrel, Tavneos, Evenity |
| Abbvie INC. | $1,531.98 | 2021-2025 | |
| Ucb, INC. | $1,165.75 | 2022-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $677.22 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Pfizer INC. | $453.46 | 2021-2025 | |
| Lilly USA, LLC | $341.43 | 2021-2024 | Taltz, Zepbound |
| Mallinckrodt Hospital Products INC. | $323.76 | 2021-2025 | Acthar |
| Glaxosmithkline, LLC. | $317.17 | 2022 | |
| Ani Pharmaceuticals, INC. | $314.68 | 2023-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $259.95 | 2022-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $238.42 | 2021-2024 | |
| Organon LLC | $216.99 | 2022-2025 | Renflexis, Hadlima |
| Aurinia Pharma U.S., INC. | $214.39 | 2021-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.35 | 2023-2025 | Ofev, Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $139.74 | 2022-2025 | Orencia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $118.77 | 2021-2025 | |
| Genentech USA, INC. | $80.10 | 2023-2024 | Actemra |
| Fresenius Kabi USA, LLC | $79.06 | 2023-2024 | Idacio |
| Sanofi-Aventis U.S. LLC | $69.99 | 2021 | |
| Sobi, INC | $62.09 | 2023-2025 | |
| Radius Health, INC. | $51.99 | 2021-2023 | Tymlos |
| Horizon Therapeutics Plc | $44.71 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $35.62 | 2021-2025 | Strensiq |
| Actelion Pharmaceuticals US, INC. | $28.02 | 2021 | |
| Tersera Therapeutics LLC | $25.72 | 2025 | Quzyttir |
| Fidia Pharma USA INC. | $17.75 | 2023 | Hymovis |
| Pharming Healthcare, INC. | $16.84 | 2022 | |
| Kyowa Kirin, INC. | $14.59 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.